SAKAR : EXPANDS GLOBAL ONCOLOGY EXPORT PORTFOLIO

• 22 marketing authorisations granted out of 190 dossiers submitted to regulators across EU, UK, APAC, Canada and LatAm • 11 site variations approved in stringent markets, including for MNCs Accord Healthcare, Tillomed Laboratories and Heumann Pharma • 2 of 7 applied CEPs approved; 21 in-house developed APIs support planned vertical integration • Commercial supplies started from the API-integrated, EU GMP approved oncology FDF manufacturing site • Business is largely export-led; proposed domestic MRP cap on oncology products will not affect Sakar as the move only regulates trade margin

Sakar Healthcare Limited

Open attachment

← Back to feed